Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: A multicenter observational cohort study (TCTG 2nd-BV study)

Toshikazu Moriwaki, Hideaki Bando, Atsuo Takashima, Kentaro Yamazaki, Taito Esaki, Keishi Yamashita, Mutsumi Fukunaga, Yasuhiro Miyake, Kenji Katsumata, Satoshi Kato, Taroh Satoh, Mitsuharu Ozeki, Eishi Baba, Shigemasa Yoshida, Narikazu Boku, Ichinosuke Hyodo

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The efficacy of bevacizumab combined with infusional 5-fluorouracil/ leucovorin (5-FU/LV) plus irinotecan (FOLFIRI) as the second-line treatment for metastatic colorectal cancer (mCRC) has not been fully clarified, although bevacizumab combined with infusional 5-FU/LV plus oxaliplatin (FOLFOX) in the second-line setting has demonstrated a survival benefit. We investigated the efficacy of bevacizumab plus FOLFIRI in mCRC patients who failed oxaliplatin-containing regimens without bevacizumab. Patients who received bevacizumab plus FOLFIRI or bevacizumab plus FOLFOX as second-line chemotherapy between July 2007 and March 2008 were registered (trial registration: UMIN000001547). Patient background data and progression-free survival (PFS), overall survival (OS), response, and bevacizumab-related adverse events were prospectively collected every 6 months. A total of 195 patients were enrolled from 26 institutions. Among them, 115 patients received bevacizumab plus FOLFIRI after failure of oxaliplatin and fluoropyrimidine (FOLFIRI+BV after OX/FU group), and 45 patients received bevacizumab plus FOLFOX after failure of irinotecan and fluoropyrimidine (FOLFOX+BV after IRI/FU group). Median PFS was 8.3 months (95% confidence interval [CI], 6.7-9.9) for the FOLFIRI+BV after OX/FU group and 7.8 months (95% CI, 5.8-9.7) for the FOLFOX+BV after IRI/FU group. Median OS was 21.6 months (95% CI, 17.6-25.6) and 16.5 months (95% CI, 11.8-21.2), respectively. Overall response rates were 25 and 29%, respectively. The most common grade ≥3 bevacizumab-related adverse events were hypertension (5.0%) and bleeding (3.8%). FOLFIRI+BV after OX/FU showed comparable efficacy to FOLFOX+BV after IRI/FU.

Original languageEnglish
Pages (from-to)2842-2848
Number of pages7
JournalMedical Oncology
Volume29
Issue number4
DOIs
Publication statusPublished - Dec 1 2012

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: A multicenter observational cohort study (TCTG 2nd-BV study)'. Together they form a unique fingerprint.

  • Cite this

    Moriwaki, T., Bando, H., Takashima, A., Yamazaki, K., Esaki, T., Yamashita, K., Fukunaga, M., Miyake, Y., Katsumata, K., Kato, S., Satoh, T., Ozeki, M., Baba, E., Yoshida, S., Boku, N., & Hyodo, I. (2012). Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: A multicenter observational cohort study (TCTG 2nd-BV study). Medical Oncology, 29(4), 2842-2848. https://doi.org/10.1007/s12032-011-0151-2